NewAmsterdam Pharma CAO exercises options, sells stock
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
NewAmsterdam Pharma Co N.V. reports that Chief Accounting Officer Louise Frederika Kooij exercised stock options for 105000 ordinary shares on July 20, 2026, then sold 105000 shares in multiple transactions at weighted average prices of $29.9600, $31.0500 and $31.7100 per share, all under a Rule 10b5-1 trading plan adopted on February 23, 2026. Reported holdings include 22000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
Insider Trade Summary 10b5-1
Exercise and Sale: 105,000 shares ($1.99M approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Kooij Louise Frederika
Role
Chief Accounting Officer
Sold
105,000 shs ($3.19M)
Approx. gross sale proceeds
$3.19M
Approx. exercise cost
$1.19M
Approx. pre-tax spread
$1.99M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option (right to buy) F5 | 25,000 | $0.00 | $0.00 |
| Exercise | Option (right to buy) F6 | 80,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares F1 | 25,000 | $11.90 | $298K |
| Exercise | Ordinary Shares F1 | 80,000 | $11.17 | $894K |
| Sale | Ordinary Shares F2, F1 | 70,200 | $29.96 | $2.10M |
| Sale | Ordinary Shares F3, F1 | 31,885 | $31.05 | $990K |
| Sale | Ordinary Shares F4, F1 | 2,915 | $31.71 | $92K |
Holdings After Transaction:
Option (right to buy) — 80,494 contracts (Direct);
Ordinary Shares — 24,353 shares (Direct)
Footnotes (6)
- F1. Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F5. The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
- F6. The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Key Figures
Shares sold: 105000 shares
First option exercise: 25000 shares
Second option exercise: 80000 shares
+4 more
7 metrics
Shares sold
105000 shares
Total ordinary shares sold on 2026-07-20 across three transactions
First option exercise
25000 shares
Options exercised at $11.9000 per share; option expiration 2033-05-18
Second option exercise
80000 shares
Options exercised at $11.1700 per share; option expiration 2034-01-01
Weighted average sale price 1
$29.9600 per share
Weighted average price; individual trades from $29.57 to $30.56
Weighted average sale price 2
$31.0500 per share
Weighted average price; individual trades from $30.58 to $31.57
Weighted average sale price 3
$31.7100 per share
Weighted average price; individual trades from $31.58 to $31.85
Unvested RSU shares
22000 shares
Ordinary shares underlying restricted stock unit awards that remain subject to vesting
Key Terms
Rule 10b5-1 trading plan, weighted average price, restricted stock unit awards, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"Reported transactions executed pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock unit awards financial
"Includes 22000 ordinary shares subject to restricted stock unit awards"
Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"shares underlying the option vested with the remaining shares vesting in equal"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider stock transactions did NewAmsterdam Pharma (NAMS) report on July 20, 2026?
NewAmsterdam Pharma reported that Chief Accounting Officer Louise Frederika Kooij exercised options for 105000 ordinary shares and sold 105000 shares on July 20, 2026 in multiple transactions at weighted average prices between $29.9600 and $31.7100 per share under a Rule 10b5-1 trading plan.
What stock options did NewAmsterdam Pharma (NAMS)'s chief accounting officer exercise?
She exercised options covering 25000 shares at an exercise price of $11.9000 per share, expiring May 18, 2033, and 80000 shares at $11.1700 per share, expiring January 1, 2034. The options were originally granted in 2023 and 2024 with four-year vesting schedules.
Were the NAMS insider transactions made under a Rule 10b5-1 trading plan?
Yes. The company states the reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Louise Frederika Kooij on February 23, 2026. Such plans pre-arrange trade timing and size, reducing the significance of day-to-day market timing.
What is Louise Frederika Kooij's role at NewAmsterdam Pharma (NAMS)?
The reporting person, Louise Frederika Kooij, serves as NewAmsterdam Pharma's Chief Accounting Officer. Her Form 4 filing details personal equity transactions in the company’s ordinary shares and related stock options connected to her executive compensation package.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates